Renaissance Technologies
CCCC icon

Renaissance Technologies’s C4 Therapeutics CCCC Stock Holding History

Renaissance Technologies’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.56M Sell
1,189,828
-1,271,987
-52% -$4.35M 0.01% 1402
2026
Q1 		$6.47M Buy
2,461,815
+859,235
+54% +$2.02M 0.01% 1214
2025
Q4 		$3.06M Buy
1,602,580
+665,630
+71% +$1.58M ﹤0.01% 1621
2025
Q3 		$2.08M Sell
936,950
-156,238
-14% -$375K ﹤0.01% 2043
2025
Q2 		$1.56M Buy
1,093,188
+878,688
+410% +$1.28M ﹤0.01% 2265
2025
Q1 		$343K Buy
+214,500
New +$640K ﹤0.01% 2879
2024
Q3 		– Sell
-235,200
Closed -$1.09M – 3553
2024
Q2 		$1.09M Sell
235,200
-170,600
-42% -$1.02M ﹤0.01% 2273
2024
Q1 		$3.31M Sell
405,800
-18,900
-4% -$146K 0.01% 1691
2023
Q4 		$2.4M Buy
424,700
+66,712
+19% +$152K ﹤0.01% 1842
2023
Q3 		$666K Sell
357,988
-158,910
-31% -$485K ﹤0.01% 2568
2023
Q2 		$1.42M Buy
516,898
+190,818
+59% +$613K ﹤0.01% 2220
2023
Q1 		$1.02M Buy
326,080
+293,580
+903% +$1.73M ﹤0.01% 2468
2022
Q4 		$192K Sell
32,500
-30,300
-48% -$251K ﹤0.01% 3435
2022
Q3 		$551K Buy
62,800
+51,300
+446% +$533K ﹤0.01% 2877
2022
Q2 		$87K Buy
+11,500
New +$101K ﹤0.01% 3882
2022
Q1 		– Sell
-31,300
Closed -$1.01M – 4098
2021
Q4 		$1.01M Buy
+31,300
New +$1.24M ﹤0.01% 2631

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Renaissance Technologies's CCCC Position: Q2 2026 in Review

Renaissance Technologies reduced its C4 Therapeutics (CCCC) stake by 52% in Q2 2026, selling an estimated $4.35M and leaving 1,189,828 shares worth $5.56M. The position accounts for 0.01% of the portfolio, ranked #1402.

Renaissance Technologies first reported a position in CCCC in Q4 2021 and has held it in 16 quarters since. The position peaked at $6.47M in Q1 2026. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Renaissance Technologies held 1,189,828 shares of C4 Therapeutics worth $5.56M as of Q2 2026.
  • Renaissance Technologies sold 1,271,987 C4 Therapeutics shares in Q2 2026, an estimated $4.35M.
  • C4 Therapeutics made up 0.01% of Renaissance Technologies's portfolio in Q2 2026, its #1402 holding.
  • Renaissance Technologies first reported a position in C4 Therapeutics in Q4 2021 and has held it in 16 quarters since.
  • Renaissance Technologies's C4 Therapeutics position peaked at $6.47M in Q1 2026.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.